Spyre Therapeutics
The Director, Analytical Sciences oversees biologics analytical development and testing across clinical and late stage mAb programs, providing strategic and operational leadership for analytical method development, validation, transfer, and GMP quality control testing.
Headquarters
Waltham, Massachusetts, United States
Company Size
11-50 employees
Founded
2023
Spyre Therapeutics is a biotechnology company focused on engineering next‑generation therapies for inflammatory bowel disease (IBD). The company applies precision engineering and translational research to design targeted biologics and therapeutic candidates intended to improve efficacy and safety for patients with IBD. Spyre advances its programs through preclinical and clinical development in collaboration with academic and industry partners, aiming to transform treatment options and patient outcomes.
Spyre Therapeutics Announces Grants of Inducement Awards
18 hours ago
Assessing Spyre Therapeutics (SYRE) Valuation After A Year Of Strong Shareholder Returns
2 days ago
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million
1 day ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Spyre Therapeutics.
3% above the average for this role
New Spyre hires get 46,600 stock options at $42.49 strike
1 day ago